d18:1/17:0

C17 Ceramide is a synthetic ceramide that contains a non-natural C17:0 fatty acid acylated to sphingosine. It has been used as a marker of arylsulfatase A and sphingolipid activator B activity in patients undergoing enzyme replacement therapy for the genetic disease metachromatic leukodystrophy.

C17 Globotriaosylceramide is a sphingolipid that has been used as an internal standard for the quantification of globotriaosylceramides in plasma and urine from patients with Fabry disease by GC-MS.

C17 Lactosylceramide is a naturally occurring sphingolipid that has been found in human brain metastases of lung adenocarcinomas but not in healthy brain tissue.

C17 Sphingomyelin, a synthetic derivative of sphingomyelin, is used as an internal standard for the quantification of sphingomyelin.

C17-Mono-sulfo galactosyl(β) ceramide (d18:1/17:0) ammonium is a lipid utilized in the preparation of lipid nanoparticles (LNP) designed for drug delivery.

C17 Glucosyl(β) ceramide (d18:1/17:0) is a lipid utilized in the formulation of lipid nanoparticles (LNP) for drug delivery applications.

C17:0 GD1a (d18:1/17:0) ammonium is a glycosphingolipid.

1-O-Acyl ceramide (d18:1/18:1/17:0) is a type of ceramide.

Sphinganine-1-phosphate (d17:0) is a sphingolipid analog of sphinganine-1-phosphate (d18:0) and sphingosine-1-phosphate (d18:1) that has a 17-carbon base. Sphinganine-1-phosphate (d17:0) levels are lower in surgical and cadaver trabecular meshwork samples isolated from patients with primary open angle glaucoma compared with control samples.